drugset / Trial / NCT00055146

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

NCT00055146

Phase 2 Completed 41 enrolled Eisai Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)

Timeline

Start
2003-03
Primary completion
2006-03
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject denileukin diftitox Protein / enzyme biologic